Navigation Links
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Date:10/13/2011

NEW YORK, Oct. 13, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology (JCO).  Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer drug candidate that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway is currently being investigated in a Phase 3 trial comparing perifosine + bortezomib + dexamethasone versus placebo + bortezomib + dexamethasone in relapsed/refractory MM patients previously treated with bortezomib.  The ongoing Phase 3 study is being conducted under a Special Protocol Assessment (SPA), and with Orphan Drug Status and Fast Track designation in MM.  Perifosine is also currently in Phase 3 clinical development for refractory advanced colorectal cancer, also under an SPA and Fast Track designation.

In this Phase 1 / 2 study, perifosine in combination with bortezomib +/- dexamethasone was evaluated in 84 heavily pre-treated patients with relapsed or relapsed/refractory MM.  All patients were required to receive prior bortezomib and most were bortezomib refractory (73%).  The combination demonstrated an overall response rate (ORR) including MR or > of 41% in all evaluable patients, with stable disease observed in an additional 41% of evaluable patients. The ORR was 65% for bortezomib-relapsed patients and 32% for patients with bortezomib-refractory disease. Median progression-free survival (PFS) was 6.4 months, wit
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. GeoVax Phase 2a Clinical Trial Completes Enrollment
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
10. Visual Healthcare to Supply Enabling Technology for Home Care Consortium Software and Support Revenues to Reach $17 M in Phase One
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
(Date:9/19/2014)... -- Over 200 runners participated in the fifth annual 5K ... Institute (ROI), hosted by Radiation Business Solutions. This year the ... Francisco.  "Donations are still coming in," ... Solutions, "but at this point, through registrations and ... ROI this year. This surpasses last year,s record of ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... PARIS , June 3, 2010 ... together global,forces in personalised medicine, has today announced the ... personalised healthcare, as Executive,Director and board member. Dr. Bruinvels ... with the board of directors, for building,its strategic framework ...
... RESEARCH TRIANGLE PARK, N.C. , June 2 ... announced that it has received a letter from the ... labeling for its respiratory products Serevent® and Advair®.  The ... FDA advisory committee meetings regarding the safety profile of ...
Cached Medicine Technology:EPEMED, the European Personalised Medicine Association, Appoints Executive Director 2EPEMED, the European Personalised Medicine Association, Appoints Executive Director 3GSK Announces Revised Product Labels for Serevent® and Advair® 2
(Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The festival season ... busy selling its newly released luxurious cocktail dresses . ... company has recently decided to launch a new promotion for ... is offered with a discounted price, from 20 to 71 ... a wide range of choices. They are provided in many ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 iFitDress.com, the ... gowns for women, has recently unveiled its new collection ... big sale for special offer on these new outfits; ... shopping season. All customers can now buy cheap ... The company’s sales representative says, “We have extensive experience ...
(Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
(Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
Breaking Medicine News(10 mins):Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2
... of an initiative to give back to the cancer ... meetings, the American Society for Radiation Oncology (ASTRO) is ... of cancer survivorship issues., Gilda,s Club South Florida will ... exhibit at ASTRO,s 53rd Annual Meeting, scheduled for October ...
... (Sept. 1, 2011) Patients often take drugs to ... develop ulcers from taking their anti-inflammatory drugs for conditions ... major problems for their small intestines, McMaster researchers have ... Digestive Health Research Institute has found those stomach acid-reducing ...
... THURSDAY, Sept. 1 (HealthDay News) -- Strokes are on ... report shows. The number of people aged 15 to ... 1995 and 2008, say researchers from the U.S. Centers for ... to the increasing numbers of young people who have diseases ...
... with ALK-rearranged non-small cell lung cancer (NSCLC) responded ... patients whose cancer did not show ALK translocation, ... of the Journal of Thoracic Oncology, the official ... of Lung Cancer (IASLC). Lung adenocarcinoma can ...
... researchers have successfully injected cultured red blood cells (cRBCs) created ... according to study results published today in ... Society of Hematology (ASH). As the global need for ... is decreasing, these study results provide hope that one day ...
... Sept. 1 (HealthDay News) -- Researchers report that they used ... successfully injected the blood cells back into the human donor ... The findings raise the possibility of creating individualized blood supplies ... they need a transfusion, a potentially dicey situation if someone ...
Cached Medicine News:Health News:Strokes Rising Among Teens, Young Adults: CDC 2Health News:Strokes Rising Among Teens, Young Adults: CDC 3Health News:Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows 2Health News:Researchers successfully perform first injection of cultured red blood cells in human donor 2Health News:Scientists Use Stem Cells for Blood 'Self-Transfusion' 2
... is an ultra-high speed, high resolution optical ... retina imaging and analysis. It ... Optical Coherence technology just emerging from clinical ... The ultra-high speed and high resolution ...
... Experience the finest surgical-quality loupes ... set the standard for innovative optical ... customer support. Delivering optimum performance with ... clear choice for medical professionals worldwide. ...
... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... performance with maximum comfort, SheerVision loupes ... professionals worldwide. All SheerVision loupes come ...
... SheerVision manufactures its signature line of award-winning ... Frame. These next generation loupes feature ... design, and are multi-coated lens for anti-glare, ... SV Sport frame offers a stylish, yet ...
Medicine Products: